Tessera Defense and Homeland Security (HLSQ)


Market Price (9/21/2026): $0.759 | Market Cap: $-Sector: Information Technology | Industry: IT Consulting & Other Services

Tessera Defense and Homeland Security (HLSQ)


Market Price (9/21/2026): $0.759
Market Cap: $-
Sector: Information Technology
Industry: IT Consulting & Other Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Weak multi-year price returns
2Y Excs Rtn is -80%, 3Y Excs Rtn is -116%

Penny stock
Mkt Price is 0.7

High stock price volatility
Vol 12M is 174%

0 Weak multi-year price returns
2Y Excs Rtn is -80%, 3Y Excs Rtn is -116%
1 Penny stock
Mkt Price is 0.7
2 High stock price volatility
Vol 12M is 174%

Valuation & Metrics

Price Chart

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
HLSQ Return------46%-46%
Peers Return1%1%20%26%70%-10%134%
S&P 500 Return27%-19%24%23%16%12%103%

Monthly Win Rates [3]
HLSQ Win Rate-----0% 
Peers Win Rate55%48%57%68%70%38% 
S&P 500 Win Rate75%42%67%75%67%44% 

Max Drawdowns [4]
HLSQ Max Drawdown------ 
Peers Max Drawdown-23%-29%-23%-21%-23%-41% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: LHX, RTX, LDOS, CACI, KTOS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/18/2026 (YTD)

How Low Can It Go

HLSQ has limited trading history. Below is the Information Technology sector ETF (XLK) in its place.

EventXLKS&P 500
2025 US Tariff Shock
  % Loss-25.7%-18.8%
  % Gain to Breakeven34.5%23.1%
  Time to Breakeven65 days79 days
2024 Yen Carry Trade Unwind
  % Loss-17.0%-7.8%
  % Gain to Breakeven20.4%8.5%
  Time to Breakeven92 days18 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-10.0%-9.5%
  % Gain to Breakeven11.2%10.5%
  Time to Breakeven15 days24 days
2022 Inflation Shock & Fed Tightening
  % Loss-33.1%-24.5%
  % Gain to Breakeven49.5%32.4%
  Time to Breakeven246 days427 days
2020 COVID-19 Crash
  % Loss-31.2%-33.7%
  % Gain to Breakeven45.2%50.9%
  Time to Breakeven78 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-23.8%-19.2%
  % Gain to Breakeven31.2%23.8%
  Time to Breakeven100 days105 days

Compare to LHX, RTX, LDOS, CACI, KTOS

In The Past

State Street Technology Select Sector SPDR ETF's stock fell -25.7% during the 2025 US Tariff Shock. Such a loss loss requires a 34.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

HLSQ has limited trading history. Below is the Information Technology sector ETF (XLK) in its place.

EventXLKS&P 500
2025 US Tariff Shock
  % Loss-25.7%-18.8%
  % Gain to Breakeven34.5%23.1%
  Time to Breakeven65 days79 days
2022 Inflation Shock & Fed Tightening
  % Loss-33.1%-24.5%
  % Gain to Breakeven49.5%32.4%
  Time to Breakeven246 days427 days
2020 COVID-19 Crash
  % Loss-31.2%-33.7%
  % Gain to Breakeven45.2%50.9%
  Time to Breakeven78 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-23.8%-19.2%
  % Gain to Breakeven31.2%23.8%
  Time to Breakeven100 days105 days
2008-2009 Global Financial Crisis
  % Loss-51.5%-53.4%
  % Gain to Breakeven106.2%114.4%
  Time to Breakeven797 days1085 days

Compare to LHX, RTX, LDOS, CACI, KTOS

In The Past

State Street Technology Select Sector SPDR ETF's stock fell -25.7% during the 2025 US Tariff Shock. Such a loss loss requires a 34.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Tessera Defense and Homeland Security (HLSQ)

Tessera Defense and Homeland Security (HLSQ) is a clinical-stage microbiome company specializing in the development of therapeutic products. The company leverages natural and engineered phage technologies, which are viruses that specifically target and kill harmful bacteria. HLSQ's efforts are aimed at addressing a wide range of medical conditions, including bacterial infections affecting skin appearance, chronic inflammatory diseases, and certain types of cancer.

HLSQ's product pipeline features several investigational therapies. BX004 is a phage therapy undergoing Phase 1b/2a clinical trials for cystic fibrosis patients suffering from chronic Pseudomonas aeruginosa respiratory infections. Another candidate, BX005, is a topical phage cocktail in Phase 1/2 study, designed to target Staphylococcus aureus bacteria associated with atopic dermatitis. The company is also developing BX003, an orally administered phage cocktail in Phase 1b/2a, which aims to target specific gut bacteria implicated in inflammatory bowel diseases (IBD) and primary sclerosing cholangitis (PSC). Additionally, HLSQ has a colorectal cancer program that utilizes engineered phage delivered intravenously to target Fusobacterium nucleatum bacteria residing within tumor microenvironments.

The primary markets for Tessera Defense and Homeland Security (HLSQ) include patients with chronic bacterial infections such as cystic fibrosis, inflammatory bowel diseases, and primary sclerosing cholangitis. The company also targets individuals with bacterial-related skin conditions like atopic dermatitis and those with colorectal cancer, providing innovative phage-based solutions to address significant unmet medical needs in these therapeutic areas.

AI Analysis | Feedback

1. Like a specialized biotech company (e.g., Moderna), but they engineer natural viruses (phages) to precisely kill specific harmful bacteria.

2. Imagine an antibiotic company, but their 'medicine' is natural viruses that specifically hunt and destroy only the harmful bacteria.

AI Analysis | Feedback

null

AI Analysis | Feedback

BiomX Inc. (symbol: HLSQ) is a clinical-stage microbiome company focused on developing phage therapies. As per the provided background, the company is primarily engaged in research, development, and clinical trials for its pipeline products, including BX004 for cystic fibrosis, BX005 for atopic dermatitis, BX003 for inflammatory bowel diseases and primary sclerosing cholangitis, and a program for colorectal cancer.

Given its clinical-stage status, BiomX Inc. does not currently have major commercial customers in the traditional sense of selling its products to individuals or other companies. Its activities are centered on advancing its therapies through the regulatory approval process rather than commercial sales.

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

null

AI Analysis | Feedback

Tessera Defense and Homeland Security (HLSQ), formerly known as BiomX Inc. (PHGE), has recently rebranded and shifted its focus from a clinical-stage microbiome company to a physical security technology platform. The company's common stock began trading under the symbol HLSQ on the NYSE American on September 11, 2026.

Tessera Defense and Homeland Security's main products and services now encompass integrated security solutions for defense, security, and critical infrastructure. These include counter-drone systems, AI-enabled command-and-control, perimeter security, wide-area surveillance, video analytics, and aerial firefighting. The company's platform integrates cameras, sensors, detection technologies, and artificial intelligence to detect threats and coordinate real-time responses.

The addressable markets for Tessera Defense and Homeland Security's main products and services, with market sizes projected for 2030, are global and include:

  • Critical Infrastructure Protection: up to $197.3 billion.
  • Emergency Response: up to $3.3 billion.
  • The company also addresses other high-growth markets such as counter-UAS, perimeter security, AI command-and-control, and video analytics.

Tessera's technologies are actively deployed in various regions, including the U.S., Mexico, Israel, UAE, and European security programs.

AI Analysis | Feedback

null

AI Analysis | Feedback

<h3>Capital Allocation Decisions for Tessera Defense and Homeland Security (HLSQ)</h3> <h4>Share Issuance</h4> <ul> <li>The company implemented a one-for-ten reverse stock split on September 9, 2026, reducing outstanding common stock and authorized shares significantly.</li> <li>As part of its acquisition strategy, BiomX issued 1,300,000 shares of common stock as partial consideration for the acquisition of Zorronet.</li> <li>Stockholders approved an amendment to the 2026 Equity Incentive Plan on June 26, 2026, increasing reserved shares by 5,460,000 to a total of 6,850,000.</li> </ul> <h4>Inbound Investments</h4> <ul> <li>The company plans to seek additional capital through equity, debt, or grants to support its operations, although there is substantial doubt about its ability to continue as a going concern.</li> <li>The NYSE American accepted the company's plan to regain compliance with listing standards, providing a compliance period through September 25, 2027.</li> </ul> <h4>Outbound Investments</h4> <ul> <li>In April 2026, the company acquired 100% of Zorronet, an AI-powered security company, and a 60% stake in DFSL, which specializes in LADAR-based detection.</li> <li>The acquisition of Zorronet involved issuing 1,300,000 shares of common stock and a $1,250,000 non-convertible promissory note.</li> <li>In August 2026, BiomX Inc. agreed to acquire a 10% stake in MEA Motomova India Private Limited/M.E.A. Testing Systems Ltd. for $0.29 million.</li> </ul> <h4>Capital Expenditures</h4> <ul> <li>The company's strategy involves acquiring specialized companies to develop a portfolio addressing emerging security gaps rather than traditional capital expenditures.</li> <li>Cash needs are expected to increase as revenues from the newly acquired DFSL and Zorronet begin in Q2 2026 and operations ramp up.</li> <li>The newly formed X Security subsidiary is funded for its 2026 operations.</li> </ul&

Peer Outperformance in IT Consulting & Other Services

null
Share of IT Consulting & Other Services constituents that HLSQ has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
insufficient peer history
3Y
insufficient peer history
5Y
insufficient peer history
null
Median price return by industry across the Information Technology sector, ranked by 5Y. IT Consulting & Other Services is HLSQ's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Electronic Manufacturing Services 9 54.5%185.9%278.9% TTMI 845% · FLEX 734% · SANM 435%
Technology Distributors 9 30.1%72.9%99.7% CLMB 337% · AVT 199% · SNX 156%
Semiconductor Materials & Equipment 26 90.9%83.7%97.5% AXTI 792% · AEHR 738% · KLAC 421%
Communications Equipment 36 16.3%86.8%75.8% AAOI 1451% · FEIM 1030% · LITE 1005%
Electronic Components 26 31.5%70.6%70.4% CLS 4032% · BELFA 1349% · COHR 435%
Technology Hardware, Storage & Peripherals 20 31.9%90.0%47.2% DELL 1150% · STX 1112% · WDC 969%
Semiconductors 55 23.7%33.9%40.8% POET 1815% · MU 1344% · NVDA 951%
Internet Services & Infrastructure 6 7.5%49.3%33.5% DOCN 64% · VRSN 44% · GDDY 38%
Electronic Equipment & Instruments 26 -16.0%9.2%-10.0% PI 225% · OSIS 117% · ACFN 108%
IT Consulting & Other Services ← 28 -24.6%-9.9%-29.0% CHRN 537268% · APLD 1265% · TSSI 669%
Application Software 123 -30.5%-13.3%-45.3% VIDA 176264% · INLX 5435% · PLTR 567%
Systems Software 68 -19.6%12.4%-54.0% QNC 478% · ZETA 406% · PANW 361%
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

HLSQLHXRTXLDOSCACIKTOSMedian
NameTessera .L3Harris.RTX Leidos CACI Int.Kratos D. 
Mkt Price0.71247.29194.00127.69626.8547.46160.84
Mkt Cap-46.0262.016.113.99.016.1
Rev LTM-22,93293,50017,6349,5681,52217,634
Op Inc LTM-2,31310,4852,080920232,080
FCF LTM-2,80810,9852,163780-1292,163
FCF 3Y Avg-2,1527,2081,645565-621,645
CFO LTM-3,29214,2062,300887-402,300
CFO 3Y Avg-2,59410,3851,800644121,800

Growth & Margins

HLSQLHXRTXLDOSCACIKTOSMedian
NameTessera .L3Harris.RTX Leidos CACI Int.Kratos D. 
Rev Chg LTM-7.3%11.8%3.4%10.9%25.5%10.9%
Rev Chg 3Y Avg-8.6%10.0%5.9%12.6%16.6%10.0%
Rev Chg Q-8.4%14.5%7.2%17.6%30.5%14.5%
QoQ Delta Rev Chg LTM-2.0%3.5%1.8%4.4%7.6%3.5%
Op Inc Chg LTM-4.5%26.0%2.9%20.4%13.2%13.2%
Op Inc Chg 3Y Avg-9.9%56.7%21.9%17.5%109.1%21.9%
Op Mgn LTM-10.1%11.2%11.8%9.6%1.5%10.1%
Op Mgn 3Y Avg-9.9%8.3%11.2%9.0%2.3%9.0%
QoQ Delta Op Mgn LTM-0.2%0.3%-0.4%0.3%-0.4%0.2%
CFO/Rev LTM-14.4%15.2%13.0%9.3%-2.6%13.0%
CFO/Rev 3Y Avg-11.9%12.5%10.6%7.4%1.4%10.6%
FCF/Rev LTM-12.2%11.7%12.3%8.2%-8.5%11.7%
FCF/Rev 3Y Avg-9.8%8.6%9.7%6.5%-4.4%8.6%

Valuation

HLSQLHXRTXLDOSCACIKTOSMedian
NameTessera .L3Harris.RTX Leidos CACI Int.Kratos D. 
Mkt Cap-46.0262.016.113.99.016.1
P/S-2.02.80.91.45.92.0
P/Op Inc-19.925.07.715.1385.819.9
P/EBIT-16.422.48.015.1228.916.4
P/E-24.833.911.725.9289.725.9
P/CFO-14.018.47.015.6-226.014.0
Total Yield-6.0%4.4%9.9%3.9%0.3%4.4%
Dividend Yield-2.0%1.4%1.3%0.0%0.0%1.3%
FCF Yield 3Y Avg-4.4%3.9%10.2%5.6%-0.7%4.4%
D/E-0.20.10.40.40.00.2
Net D/E-0.20.10.40.4-0.10.2

Returns

HLSQLHXRTXLDOSCACIKTOSMedian
NameTessera .L3Harris.RTX Leidos CACI Int.Kratos D. 
1M Rtn-44.4%-6.8%-7.6%-9.4%-3.2%-17.0%-8.5%
3M Rtn-44.4%-15.7%4.9%19.6%34.4%-12.5%-3.8%
6M Rtn-44.4%-29.3%-1.4%-22.5%3.4%-43.9%-25.9%
12M Rtn-44.4%-11.5%24.4%-31.1%25.7%-41.2%-21.3%
3Y Rtn-44.4%50.6%183.5%42.9%100.5%230.3%75.5%
1M Excs Rtn-43.7%-9.6%-11.2%-11.7%-4.7%-20.9%-11.5%
3M Excs Rtn-46.4%-17.7%2.9%17.6%32.4%-14.5%-5.8%
6M Excs Rtn-60.2%-47.2%-18.4%-38.3%-13.5%-64.6%-42.8%
12M Excs Rtn-60.3%-26.7%8.5%-45.6%10.6%-53.2%-36.2%
3Y Excs Rtn-115.7%-16.4%101.3%-31.8%27.3%153.4%5.4%

Comparison Analyses

null

Segment Financials

Operating Income by Segment
$ Mil2024
Clinical stage product discovery company developing products using both natural and engineered-45
Total-45


Assets by Segment
$ Mil20242023202220212020
Clinical stage product discovery company developing products using both natural and engineered4325467870
Total4325467870


Price Behavior

null
HLSQ Betas & Captures as of 8/31/2026

 1M2M3M6M1Y3Y
Beta      
Up Beta
Down Beta
Up Capture0%0%0%0%0%0%
Bmk +ve Days10213268138427
Stock +ve Days      
Down Capture-0%-0%-0%-0%-0%-0%
Bmk -ve Days11213259113324
Stock -ve Days      

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with HLSQ
HLSQ-44.5%174.2%-15.27-
Sector ETF (XLK)40.5%26.4%1.2547.1%
Equity (SPY)16.9%12.9%0.9442.0%
Gold (GLD)19.1%29.3%0.6067.0%
Commodities (DBC)46.3%20.6%1.7336.3%
Real Estate (VNQ)4.9%13.6%0.102.0%
Bitcoin (BTCUSD)-30.6%44.3%-0.7045.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with HLSQ
HLSQ-11.1%174.2%-15.27-
Sector ETF (XLK)20.2%25.9%0.6947.1%
Equity (SPY)12.9%17.2%0.5742.0%
Gold (GLD)19.1%18.8%0.8367.0%
Commodities (DBC)11.2%19.5%0.4536.3%
Real Estate (VNQ)1.1%18.8%-0.052.0%
Bitcoin (BTCUSD)12.5%52.5%0.4245.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with HLSQ
HLSQ-5.7%174.2%-15.27-
Sector ETF (XLK)24.4%25.0%0.8847.1%
Equity (SPY)15.1%18.0%0.7242.0%
Gold (GLD)12.1%16.4%0.6167.0%
Commodities (DBC)8.3%18.1%0.3736.3%
Real Estate (VNQ)4.4%20.7%0.182.0%
Bitcoin (BTCUSD)62.6%66.2%1.0245.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

SEC Filings

Expand for More
Report DateFiling DateFiling
12/31/202403/25/202510-K
09/30/202411/14/202410-Q
06/30/202408/14/202410-Q
03/31/202405/20/202410-Q
12/31/202304/04/202410-K
09/30/202311/14/202310-Q
06/30/202308/09/202310-Q
03/31/202305/15/202310-Q
12/31/202203/29/202310-K
09/30/202211/09/202210-Q
06/30/202208/10/202210-Q
03/31/202205/11/202210-Q
12/31/202103/30/202210-K
09/30/202111/15/202110-Q
06/30/202108/16/202110-Q
03/31/202105/24/202110-Q
Collapse to Preview
Report DateFiling DateFiling
12/31/202403/25/202510-K
09/30/202411/14/202410-Q
06/30/202408/14/202410-Q
03/31/202405/20/202410-Q
12/31/202304/04/202410-K
09/30/202311/14/202310-Q
06/30/202308/09/202310-Q
03/31/202305/15/202310-Q
12/31/202203/29/202310-K
09/30/202211/09/202210-Q
06/30/202208/10/202210-Q
03/31/202205/11/202210-Q
12/31/202103/30/202210-K
09/30/202111/15/202110-Q
06/30/202108/16/202110-Q
03/31/202105/24/202110-Q
12/31/202003/31/202110-K
09/30/202011/12/202010-Q
06/30/202008/13/202010-Q
03/31/202005/14/202010-Q
12/31/201903/26/202010-K
09/30/201910/16/201910-Q
06/30/201908/21/201910-K
03/31/201905/10/201910-Q
12/31/201802/06/201910-Q
09/30/201812/14/2018424B4
Core Cache Last Updated: 9/20/2026